FILTER

FILTERED INTERVIEW RESULTS

Olivier Schorochoff & Weid Vereycken

MANAGING DIRECTOR & REGIONAL MANAGER HAUT-KATANGA AND LUALABA, GARDAWORLD
GardaWorld is the largest privately-owned security services company in the world, with an annual turnover of around US$4 billion, a total of 120,000 employees.

Andrew Grove

MANAGING DIRECTOR, CHESSER RESOURCES
Chesser Resources explains progress at its Diamba Sud project in Senegal.

Mouhammed Kebe

PARTNER, GENI AND KEBE
Gene and Kebe comment on how West Africa is evolving to better welcome investments.

Caigen Wang

FOUNDER AND CEO, TIETTO MINERALS
"We are absolutely thrilled to have successfully completed an A$130 million two-tranche placement with no debt. Abujar is now fully funded to commence production in late CY2022."

Joshua Olmsted

PRESIDENT AND COO – AMERICAS, FREEPORT-MCMORAN
Freeport-McMoral updates GBR on its strategy for Chile.

Christian Cavagnaro

MANAGING DIRECTOR, TAKRAF CHILE
TAKRAF gives examples of how its material handling solutions benefit mines.

José Augusto Palma

NATIONAL SOCIETY OF MINING, PETROLEUM AND ENERGY (SNMPE); PRESIDENT OF THE ORGANIZING COMMITTEE, INTERNATIONAL GOLD, SILVER AND COPPER SYMPOSIUM
José Augusto Palma discusses the novelties of the 14th edition of the Gold, Silver and Copper Symposium and analyzes the competitiveness of Peru as a mining country.

Iván Arriagada

CEO, ANTOFAGASTA PLC
Iván Arriagada provides an update on Antofagasta Minerals’ Chilean operations.

Don Lindsay

PRESIDENT & CEO, TECK RESOURCES LIMITED
Don Lindsay details the development of Teck’s QB2 project in Chile.

Joshua Olmsted

PRESIDENT AND COO – AMERICAS, FREEPORT-MCMORAN
Joshua Olmsted outlines Freeport McMoRan’s growth strategy in the Americas.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS